697739-24-5

Usage

Uses

Used in Organic Synthesis:
2-Chloro-6-methoxypyridine-4-boronic acid pinacol ester is used as a reagent in organic synthesis for its ability to participate in Suzuki coupling reactions and other cross-coupling processes. Its role in these reactions is crucial for the formation of new carbon-carbon bonds, which are essential in creating a wide range of organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-CHLORO-6-METHOXYPYRIDINE-4-BORONIC ACID PINACOL ESTER is used as a building block for the creation of diverse molecular scaffolds. These scaffolds have potential pharmaceutical applications due to the compound's unique structure and functional groups, which can be tailored to target specific biological pathways or receptors.
Used in Drug Discovery:
2-Chloro-6-methoxypyridine-4-boronic acid pinacol ester is utilized in drug discovery as a key component in the synthesis of complex organic molecules with potential biological activity. Its versatility allows researchers to explore new avenues in the development of therapeutic agents that can address various medical conditions.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, 2-CHLORO-6-METHOXYPYRIDINE-4-BORONIC ACID PINACOL ESTER is employed as a valuable tool for the synthesis of new drug candidates. Its participation in cross-coupling reactions enables the creation of novel compounds with potential therapeutic properties, contributing to the advancement of pharmaceutical research and development.

Upstream product

• 17228-64-7 6-chloro-2-methoxypyridine 
• 73183-34-3 bis(pinacol)diborane 

Relevant academic research and scientific papers

Understanding the Activation of Air-Stable Ir(COD)(Phen)Cl Precatalyst for C-H Borylation of Aromatics and Heteroaromatics

A newly developed robust catalyst [Ir(COD)(Phen)Cl] (A) was used for the C-H borylation of three dozen aromatics and heteroaromatics with excellent yield and selectivity. Activation of the catalyst was identified by the use of catalytic amounts of water, alcohols, etc., when B2pin2 was used in noncoordinating solvents, while for THF catalytic use of HBpin was required. The results were on par with the in situ based expensive system [Ir(OMe)(COD)]2/dtbbpy or Me4Phen.

Microwave-assisted, Ir-catalyzed aromatic C-H borylation

One-step conversions of 1,3-disubstituted benzenes to aryl boronates and 2,6-disubstituted pyridines to heteroaryl boronates are described. Microwave heating was used for all reactions. [(COD)Ir(μ-OMe)]2 and 4,4′-di-tert-butyl-2,2′-bipyridine w

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.